US equities |
MU $971.36 ▲+4.59% META $614.67 ▼-0.89% TSLA $401.64 ▼-1.43% SPCX $144.74 ▼-2.58% SNDK $1,378.98 ▲+5.68% NVDA $217.31 ▼-0.29% SKHY $163.41 ▲+12.41% STX $677.62 ▲+1.46%
FinancialContent

ProKidney Corp. - Class A Ordinary Shares (NQ:PROK)

1.515 +0.005 (+0.33%)
Delayed Quote Updated: 12:01 PM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ProKidney Corp. - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
ProKidney Targets Q2 2027 Phase III Readout as Rilparencel Enrollment Surpasses 500 ↗
ProKidney (NASDAQ:PROK) said it remains on track to report top-line results from the interim analysis of its Phase III PROACT 1 study in the second quarter of 2027, following stronger-than-expected... 
Via MarketBeat
News headline image
ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Appoints Kenneth Locke as Chief Technical Officer
Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses toward the... 
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Reports First Quarter 2026 Financial Results and Business Highlights
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer
Veteran commercial executive brings deep nephrology and specialty biopharma leadership experience as ProKidney advances rilparencel toward potential commercialization 
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Reports Full Year 2025 Financial Results and Business Highlights
From ProKidney
Via GlobeNewswire
News headline image
ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Corp (NASDAQ:PROK) Reports Q3 2025 Earnings and Clinical Progress ↗
ProKidney (PROK) reports Q3 2025 results, beating EPS estimates. Key updates include strong Phase 3 trial enrollment and a confirmed FDA accelerated approval pathway for its kidney disease therapy. 
Via Chartmill
News headline image
Eledon Pharmaceuticals (ELDN) Plummets Nearly 50% Amidst Mixed Phase 2 Trial Results, Sparking Investor Concern
San Diego, CA – November 10, 2025 – Eledon Pharmaceuticals (NASDAQ: ELDN) witnessed a dramatic collapse in its stock price, shedding nearly 50% of its value following the announcement of mixed results... 
Via MarketMinute
News headline image
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025
From ProKidney
Via GlobeNewswire
News headline image
ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025
From ProKidney
Via GlobeNewswire
News headline image
SPAC King Chamath Palihapitiya Tells Retail Investors To Stay Away From His New SPAC ↗
Chamath Palihapitiya is back with another SPAC. This time he's telling retail investors to stay away. Here's why. 
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Friday? ↗
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
What's going on in today's session ↗
Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference
From ProKidney
Via GlobeNewswire
News headline image
Prediction: Chamath Palihapitiya's $250 Million SPAC Could Create the Next Palantir for America's Energy Grid ↗
Chamath Palihapitiya is launching a $250 million SPAC, called American Exceptionalism Acquisition Corp. 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Chamath Palihapitiya Returns To SPACs: Past 18 Deals, Investments Average Loss Of 14% ↗
Chamath Palihapitiya is back with a new SPAC. Many investors will remember past SPACs the investor was involved with and the poor performance track record. 
Via Benzinga
News headline image
ProKidney Reports 78 Percent Gain in Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
ProKidney Corp (NASDAQ:PROK) Reports Mixed Q2 2025 Results with Regulatory Progress and Narrower Loss ↗
ProKidney Corp. (PROK) reports Q2 2025 results with unexpected revenue and a narrower loss than expected. FDA progress on rilparencel and Phase 3 trial updates highlight key milestones. Cash runway... 
Via Chartmill
News headline image
ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
From ProKidney
Via GlobeNewswire
News headline image
Meet the Biotech Stock That Rocketed 775% Higher ↗
Via The Motley Fool
News headline image
This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion. But Is It a Buy? ↗
Via The Motley Fool
News headline image
Unusual volume stocks are being observed in Tuesday's session. ↗
The trading volume of these stocks is deviating from the norm in today's session. 
Via Chartmill
News headline image
Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >